OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS Share Price
Certificat
DE000SF78B33
| Market Closed - Deutsche Boerse AG 01:17:36 22/06/2024 am IST | ||
| 30.08 EUR | +0.20% |
|
| Current month | +5.92% | ||
| 1 month | +11.37% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 21/24/21 | 30.08 | +0.20% |
| 20/24/20 | 30.02 | +2.35% |
| 19/24/19 | 29.33 | -1.18% |
| 18/24/18 | 29.68 | -2.43% |
| 17/24/17 | 30.42 | -2.12% |
Delayed Quote Deutsche Boerse AG
Last update June 22, 2024 at 01:17 am IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SF78B3 |
| ISIN | DE000SF78B33 |
| Date issued | 08/09/2021 |
| Strike | 148.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.21 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 31.27 € |
|---|---|
| Lowest since issue | 4.77 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
468.7
USD
Average target price
463.4
USD
Spread / Average Target
-1.13%
- Stock Market
- Certificates
- Certificat
